Terns Pharmaceuticals Inc (TERN)

Currency in USD
52.710
+0.030(+0.06%)
Closed·
52.615-0.096(-0.18%)
·
TERN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
52.67052.760
52 wk Range
2.21553.190
Key Statistics
Prev. Close
52.68
Open
52.69
Day's Range
52.67-52.76
52 wk Range
2.215-53.19
Volume
4.1M
Average Vol. (3m)
5.42M
1-Year Change
2,096.25%
Book Value / Share
9.25
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TERN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
53.625
Upside
+1.74%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Terns Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals Inc SWOT Analysis


Future Catalysts
Upcoming trial results and potential partnerships could significantly impact stock performance, with analyst price targets ranging from $15 to $20
Market Dynamics
Explore how Terns navigates competitive CML and obesity treatment landscapes, with analysts noting potential for significant market share capture
Financial Health
Strong cash position of $315 million provides runway into 2028, supporting ongoing clinical trials without immediate financing concerns
Promising Pipeline
Terns Pharmaceuticals' TERN-701 for CML and TERN-601 for obesity show potential to disrupt markets, with key data readouts expected in Q4 2025
Read full SWOT analysis

Compare TERN to Peers and Sector

Metrics to compare
TERN
Peers
Sector
Relationship
P/E Ratio
−63.3x−8.1x−0.5x
PEG Ratio
−8.33−0.110.00
Price / Book
6.1x4.2x2.6x
Price / LTM Sales
-7.0x3.2x
Upside (Analyst Target)
0.5%47.8%47.6%
Fair Value Upside
Unlock6.4%6.1%Unlock

Analyst Ratings

1 Buy
9 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 53.625
(+1.74% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Leerink Partners
Hold53.00+0.55%-DowngradeApr 08, 2026
Mizuho
Hold53.00+0.55%-MaintainApr 08, 2026
William Blair
Hold---DowngradeApr 07, 2026
Truist Securities
Hold53.00+0.55%56.00DowngradeMar 30, 2026
Barclays
Hold53.00+0.55%56.00DowngradeMar 30, 2026

Earnings

Latest Release
Mar 31, 2026
EPS / Forecast
-0.25 / -0.30
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

TERN Income Statement

People Also Watch

142.520
AAOI
-2.64%
18.190
ERAS
+1.90%
62.930
AXTI
-6.49%
824.01
LITE
-3.37%
66.41
LASR
-0.69%

FAQ

What Is the Terns Pharmaceuticals (TERN) Stock Price Today?

The Terns Pharmaceuticals stock price today is 52.710 USD.

What Stock Exchange Does Terns Pharmaceuticals Trade On?

Terns Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Terns Pharmaceuticals?

The stock symbol for Terns Pharmaceuticals is "TERN."

What Is the Terns Pharmaceuticals Market Cap?

As of today, Terns Pharmaceuticals market cap is 6.080B USD.

What Is Terns Pharmaceuticals's Earnings Per Share (TTM)?

The Terns Pharmaceuticals EPS (TTM) is -1.033.

When Is the Next Terns Pharmaceuticals Earnings Date?

Terns Pharmaceuticals will release its next earnings report on May 18, 2026.

From a Technical Analysis Perspective, Is TERN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Terns Pharmaceuticals Stock Split?

Terns Pharmaceuticals has split 0 times.

How Many Employees Does Terns Pharmaceuticals Have?

Terns Pharmaceuticals has 59 employees.

What is the current trading status of Terns Pharmaceuticals (TERN)?

As of Apr 15, 2026, Terns Pharmaceuticals (TERN) is trading at a price of 52.710 USD, with a previous close of 52.680 USD. The stock has fluctuated within a day range of 52.670 USD to 52.760 USD, while its 52-week range spans from 2.215 USD to 53.190 USD.

What Is Terns Pharmaceuticals (TERN) Price Target According to Analysts?

The average 12-month price target for Terns Pharmaceuticals is 53.625 USD, with a high estimate of 58 USD and a low estimate of 53 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +1.74% Upside potential.

What Is the TERN After Hours Price?

TERN's last after hours stock price is 52.615 USD, the stock has decreased by -0.096, or -0.180%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.